Alpha 2.0
Login Register
» Authors » Sylvain Ladoire

Sylvain Ladoire

Explore the profile of Sylvain Ladoire including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 164
Citations 7372
Followers 0
Related Specialties
Oncology
Urology
Allergy & Immunology
Top 10 Co-Authors
Francois Ghiringhelli
Laurent Arnould
Isabelle Desmoulins
Romain Boidot
Valentin Derangere
Aurelie Bertaut
Charles Coutant
Julie Vincent
Joaquim Bellmunt
Lionel Apetoh
Published In
Eur J Cancer
Oncoimmunology
Cancers (Basel)
Eur Urol
Bull Cancer
Affiliations
Soon will be listed here.
Recent Articles
1.
Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption
Lopez M, Spehner L, Andre F, Viot J, Seffar E, Marguier A, et al.
Breast Cancer Res . 2025 Feb; 27(1):19. PMID: 39920833
Background: Breast Cancer (BC) is the most common type of cancer in women around the world and 70% of cases are hormone-receptor positive (HR+). In 40% of cases, a key...
2.
Prevalence, clinicopathologic features and long-term overall survival of early breast cancer patients eligible for adjuvant abemaciclib and/or ribociclib
Ladoire S, Kamga A, Galland L, Reda M, Desmoulins I, Mayeur D, et al.
NPJ Breast Cancer . 2025 Feb; 11(1):10. PMID: 39893163
Adjuvant CDK4/6 inhibitors (abemaciclib and ribociclib) associated with endocrine therapy reduced the risk of relapse for HR+/HER2- early breast cancer (eBC) patients in the monarchE and NATALEE trials. In this...
3.
The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma
Pignot G, Margue G, Bigot P, Lang H, Balssa L, Roubaud G, et al.
World J Urol . 2025 Jan; 43(1):54. PMID: 39747746
Purpose: Immune Checkpoints Inhibitors (ICI) have changed the therapeutic landscape of metastatic renal cell carcinoma first-line treatment with complete response (CR) at metastatic sites observed in 10 to 15% of...
4.
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
Turner N, Saura C, Aftimos P, van den Tweel E, Oesterholt M, Koper N, et al.
J Clin Oncol . 2024 Oct; 43(5):513-523. PMID: 39442070
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapy is standard of care for HER2-positive (HER2+) breast cancer, but most patients develop progressive disease with persistent HER2 expression. No definitive...
5.
Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry
Ladoire S, Kamga A, Galland L, Desmoulins I, Mayeur D, Kaderbhai C, et al.
Breast . 2024 Sep; 78:103789. PMID: 39243563
Background: The results of the OlympiA study led to the approval of a PARP inhibitor (olaparib) as adjuvant treatment for early breast cancer (eBC) at high risk of relapse in...
6.
Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, co-mutated metastatic NSCLC
Roussot N, Thibaudin M, Fumet J, Daumoine S, Hampe L, Rebe C, et al.
Front Immunol . 2024 Aug; 15:1437961. PMID: 39170614
A patient with a PD-L1-negative, TMB-low, co-mutated metastatic non-small cell lung cancer (NSCLC) experienced a multisite radiological progression at 3 months after initiation of chemoimmunotherapy as first-line treatment for metastatic...
7.
Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response From Histologic Slides
Bergstrom E, Abbasi A, Diaz-Gay M, Galland L, Ladoire S, Lippman S, et al.
J Clin Oncol . 2024 Jul; 42(30):3550-3560. PMID: 39083703
Purpose: Cancers with homologous recombination deficiency (HRD) can benefit from platinum salts and poly(ADP-ribose) polymerase inhibitors. Standard diagnostic tests for detecting HRD require molecular profiling, which is not universally available....
8.
Definitive radio(chemo)therapy versus upfront surgery in the treatment of HPV-related localized or locally advanced oropharyngeal squamous cell carcinoma
Baude J, Guigou C, Thibouw D, Vulquin N, Folia M, Constantin G, et al.
PLoS One . 2024 Jul; 19(7):e0307658. PMID: 39052674
Background: The treatment of stage I-III HPV+ oropharyngeal squamous cell carcinoma (HPV-OPSCC) is based on either surgery ± adjuvant therapy or exclusive radio±chemotherapy. We sought to compare these two therapeutic...
9.
Respective contribution of baseline clinical data, tumour metabolism and tumour blood-flow in predicting pCR after neoadjuvant chemotherapy in HER2 and Triple Negative breast cancer
Payan N, Presles B, Coutant C, Desmoulins I, Ladoire S, Beltjens F, et al.
EJNMMI Res . 2024 Jul; 14(1):60. PMID: 38965124
Background: The aim of this study is to investigate the added value of combining tumour blood flow (BF) and metabolism parameters, including texture features, with clinical parameters to predict, at...
10.
Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial
Alexandre J, Oudard S, Golmard L, Campedel L, Mseddi M, Ladoire S, et al.
Clin Pharmacokinet . 2024 Jul; 63(7):1025-1036. PMID: 38963459
Background And Objective: Trough abiraterone concentration (ABI C) of 8.4 ng/mL has been identified as an appropriate efficacy threshold in patients treated for metastatic castration-resistant prostate cancer (mCRPC). The aim...